Will Investors Profit from Geron's Road to Recovery?
The Food and Drug Administration recently lifted a partial hold on Geron's imetelstat for a trial in myelofibrosis. The drug has shown great efficacy data so far, sending myelofibrosis patients into complete remission -- something Incyte's Jakafi, the only approved drug for myelofibrosis, can't do.
But the trial that was reinstated was just an investigator-sponsored trial. To release the clinical hold on company-run trials in essential thrombocythemia, polycythemia vera, and multiple myeloma, Geron has to present more preclinical data and analyze the clinical data to convince the FDA that imetelstat isn't causing permanent liver damage.
Watch the video below for more thoughts from senior biotech specialist Brian Orelli and health-care analyst David Williamson on Geron's prospects and whether Incyte has anything to worry about.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Will Investors Profit from Geron's Road to Recovery? originally appeared on Fool.com.Brian Orelli, David Williamson, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.